Dutch Court Case On Drug Humira Assesses Whether Its Price Was 'Excessive'

Contributing sentiments towards policy:

59% : In the Netherlands, when a drug launches, manufacturers face multiple entities, including the National Health Care Institute and the Ministry of Health, Welfare, and Sport, with whom they negotiate the medication's pricing and reimbursement.
55% : Additionally, the organization seeks a way to mandate more transparency from pharmaceutical firms with respect to research and development costs, the share of public funding and profit margins.
52% : The Dutch Healthcare Authority, an agency of the Dutch Ministry of Health, Welfare and Sport released a report last month which noted that annual per patient spending on adalimumab-based products in the Netherlands fell nearly 90% in 2018, from €10,400($11,713) during Humira's patent period to €1,300($1,464) once biosimilar competition was introduced.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.